Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13045903 | 0.78 | HPGD (0.46) | HPGDTSHRLMNAMAPT | |
| SCHEMBL20730399 | 0.77 | ESR1 (0.40) | HPGDTSHRLMNA | |
| SCHEMBL13827584 | 0.74 | TRPM8 (0.36) | LMNAGSK3BL3MBTL1 | |
| SCHEMBL20682498 | 0.73 | HPGD (0.42) | HPGDTSHRLMNA | |
| SCHEMBL21917834 | 0.73 | GPR84 (0.35) | HPGDTSHRLMNA | |
| SCHEMBL20938923 | 0.71 | MAPK14 (0.42) | HPGDTSHRLMNAKDM4ENPC1 | |
| SCHEMBL1204717 | 0.69 | HCAR2 (0.46) | HPGDTSHRNPC1MAPTRAB9A | |
| SCHEMBL13004470 | 0.69 | HPGD (0.55) | HPGDTSHRLMNAMAPT | |
| SCHEMBL5207242 | 0.69 | NPC1 (0.43) | HPGDTSHRLMNANPC1MAPT | |
| SCHEMBL16359170 | 0.69 | HPGD (0.36) | HPGDTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292300-A1 | DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-23 | — | — | US | disclosed |
| US-11078185-B2 | Mycobacterium tuberculosis—thioredoxin reductase inhibitor as an antitubercular agent | TECHNISCHE UNIVERSITAT DORTMUND (DE) | 2021-08-03 | — | — | US | disclosed |
| EP-3490983-B1 | DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20200123130-A1 | Myobacterium Tuberculosis-Thioredoxin Reductase Inhibitor as an Antitubercular Agent | TECHNISCHE UNIVERSITAT DORTMUND (DE) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123130-A1 | Myobacterium Tuberculosis-Thioredoxin Reductase Inhibitor as an Antitubercular Agent | TXNRD1, TXNRD3, TXNRD2 | HPGD 209/4885TSHR 660/4885LMNA 3848/4885 |
| US-20210292300-A1 | DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS | TLR9, TLR7, TLR8 | HPGD 4352/4885TSHR 633/4885LMNA 2699/4885 |
| US-11078185-B2 | Mycobacterium tuberculosis—thioredoxin reductase inhibitor as an antitubercular agent | TXNRD3, TXNRD1, TXN | HPGD 156/4885TSHR 416/4885LMNA 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.